Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lumosa Therapeutics Co., Ltd.
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 to 90 years
NIHSS of 4 to 30
Diagnosis of AIS within 24 hours after stroke symptoms onset
You may not be if
Treatement with approved drug during the current AIS
Pre-stroke disability
Imaging evidence of acute intracranial hemorrhage, intraparenchymal tumor, arteriovenous malformations, other central nervous system lesions that could increase bleeding risk, or aneurysm requiring treatment
Suspected subarachnoid hemorrhage
Seizure
Uncontrolled hypertension
INR \>1.7 and/or abnormal aPTT or platelet count \<100,000/mm3
Blood glucose concentration \<50 mg/dL or \>400 mg/dL
Lactating or pregnant subjects or those planning to become pregnant during the study
Received anticoagulants and/or antiplatelet therapy and glycoprotein IIb/IIIa inhibitors within 48 hours
AIS, myocardial infarction, serious head trauma or major surgery within 90 days
Bleeding event within 21 days
Puncture of noncompressible vessels within 7 days
Severe hepatic, renal, and/or infectious disease
Clareo Health | A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
